17,261 trials
Rheumatoid Arthritis
Primary: Percent of Participants Achieving an American College of Rheumatology (ACR) 20% Response Rate — 39.3; 76.3; 55.0; 73.3 percentage of participants
Corona Virus Infection · ARDS · ARDS, Human
Primary: Number of Participants With Pre-Specified Infusion Associated Adverse Events — 1; 1; 1; 1 Participants
Phelan-McDermid Syndrome
Primary: Change in Aberrant Behavior Checklist — -7.44; -2.42; -5; -1.71 score on a scale
COVID-19
Primary: Time to Improvement in Oxygenation — 4 Days
Cow's Milk Allergy
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 15; 11 Participants
Recurrent Colorectal Carcinoma · Stage IVA Colorectal Cancer · Stage IVB Colorectal Cancer
Primary: To Examine the Adverse Event Profile — 21; 20; 17; 16 participants
Covid19
Primary: Mortality — 2; 10 participants
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Number of Participants With Complete Response (CR) — 1 Participants
Multiple Myeloma
Primary: Proportion of Participants With Relapsed Multiple Myeloma With Progression-free (PFS) — 0.31 Proportion of participants PFS
HIV Infections
Primary: Pharmacokinetic (PK) Parameter: Single-dose Area-under-the-curve (AUC0-∞) of Doravirine (DOR) (Cohort 1) — 34.8 µM*hr
COVID-19
Primary: Safety of Clazakizumab for the Treatment of Patients With COVID-19 Disease — 3; 3; 6; 8 Adverse Events — p=0.10
Fanconi Anemia
Primary: Number of Participants Experiencing Graft Failure — 1; 0; 0; 0 Participants
Postpartum Depression
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 4; 0 Participants
Cytokine Release Syndrome · COVID19
Primary: C-reactive Protein (CRP) Levels at Baseline and Day 14 — 75.45; 59.8; 41.9; 38.7 mg/L
Non-Transitional Cell Carcinoma of the Urothelial Tract · Small Cell of the Bladder · Adenocarcinoma of the Bladder
Primary: Overall Response Rate — 2; 11; 2 Participants